Evisceration with primary orbital implant in endophthalmitis/ panophthalmitis

To describe the outcome of Evisceration with the primary orbital implant in non-seeing eyes with and without ocular infection (endophthalmitis/panophthalmitis). A prospective, nonrandomized comparative case series research was performed from 2019 to 2022. Patients with the least postoperative follow-up of 6 months were included in the study. One seventy-three eyes of one seventy-three patients were included. Group A involved the infective patients, and Group B included all noninfective blind eyes. Nonporous PMMA implants were used for all cases, and the main outcome measure was the successful retention of the primary implant. All types of complications and satisfactory prosthesis fitting were also observed. The mean (±SD) age was 45.689 ± 11.34 years, with males (53.2%) predominant. All except 11 cases could retain the primary implant successfully. Primary orbital implants were exposed in nine (5.2%) cases (four in Group A and five in Group B), and Extrusion of the primary orbital implant occurred in two (1.1%) cases, and all extrusion occurred in Group A. One hundred fifty-six (90.2%) patients underwent successful prosthesis fitting with better cosmesis. The difference in major complications like implant exposure and implant extrusion between the groups was not statistically significant (P value equals 0.0879, Fisher exact test). Evisceration with a primary orbital implant is feasible in both infective (endophthalmitis/ panophthalmitis) and noninfective blind eyes. It provides a better postoperative cosmesis to the anophthalmic socket.